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ABSTRACT  16 
The oncogenic microRNA miR-155 is the most frequently upregulated miRNA in 17 
Epstein-Barr virus (EBV)-positive B cell malignancies and is upregulated in other non-18 
viral lymphomas. Both the EBV nuclear antigen 2 (EBNA2), and B cell transcription 19 
factor, interferon regulatory factor 4 (IRF4) are known to activate transcription of the 20 
host cell gene from which miR-155 is processed (miR-155HG, BIC). EBNA2 also 21 
activates IRF4 transcription indicating that EBV may upregulate miR-155 through direct 22 
and indirect mechanisms. The mechanism of transcriptional regulation of IRF4 and miR-23 
155HG by EBNA2 however has not been defined. We demonstrate that EBNA2 can 24 
activate IRF4 and miR-155HG expression through specific upstream enhancers that are 25 
dependent on the Notch signaling transcription factor RBPJ, a known binding partner of 26 
EBNA2. We demonstrate that in addition to activation of the miR-155HG promoter, IRF4 27 
can also activate miR-155HG via the upstream enhancer also targeted by EBNA2. Gene 28 
editing to remove the EBNA2- and IRF4-responsive miR-155HG enhancer located 60 kb 29 
upstream of miR-155HG led to reduced miR155HG expression in EBV-infected cells. 30 
Our data therefore demonstrate that specific RBPJ-dependent enhancers regulate the 31 
IRF4-miR-155 expression network and play a key role in the maintenance of miR-155 32 
expression in EBV-infected B cells. These findings provide important insights that will 33 
improve our understanding of miR-155 control in B cell malignancies. 34 
 35 
 36 
 37 
 38 
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IMPORTANCE  39 
MicroRNA-155 (miR-155) is expressed at high level in many human cancers particularly 40 
lymphomas. Epstein-Barr virus (EBV) infects human B cells and drives the development 41 
of numerous lymphomas. Two EBV-encoded genes (LMP1 and EBNA2) upregulate 42 
miR-155 expression and miR-155 expression is required for the growth of EBV-infected 43 
B cells. We show that the EBV transcription factor EBNA2 upregulates miR-155 44 
expression by activating an enhancer upstream from the miR-155 host gene (miR-45 
155HG) from which miR-155 is derived. We show that EBNA2 also indirectly activates 46 
miR-155 expression through enhancer-mediated activation of IRF4. IRF4 then activates 47 
both the miR-155HG promoter and the upstream enhancer, independently of EBNA2. 48 
Gene editing to remove the miR-155HG enhancer leads to a reduction in miR-155HG 49 
expression. We therefore identify enhancer-mediated activation of miR-155HG as a 50 
critical step in promoting B cell growth and a likely contributor to lymphoma 51 
development. 52 
  53 
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INTRODUCTION  54 
The oncogenic microRNA (miRNA) miR-155 maps within and is processed from a non-55 
coding RNA transcribed from the B-cell Integration Cluster (BIC) gene by RNA 56 
polymerase II (pol II) (1). BIC was previously identified as a proto-oncogene activated by 57 
proviral insertion in avian leucosis virus-induced lymphomas (2, 3). The miR-155 locus 58 
is highly conserved across species and in humans lies within the third exon of BIC (miR-59 
155 host gene; miR-155HG). MiR-155 appears to play a key role in the regulation of B 60 
lymphocyte function. Transcription of miR-155HG is activated upon B cell receptor 61 
signaling and in murine models dysfunction or loss of miR-155 in B lymphocytes causes 62 
a severe decrease in antibody-induced signaling (4, 5). Overexpression of miR-155 in 63 
mice results in the development of precursor B lymphoproliferative disorders and B cell 64 
lymphomas (6). MiR-155 expression is highly upregulated in a number of human 65 
lymphomas including Hodgkin's lymphoma (HL) and diffuse large cell B-cell lymphoma 66 
(DLBCL)(4, 7, 8). The basis of the oncogenic activity of miR-155 has not been fully 67 
elucidated however a number of target genes that regulate B cell proliferation and 68 
survival have been identified. These include transcription regulators, receptors and 69 
signaling pathway components e.g. HDAC4, PIK3R1, SMAD5, SHIP1, PU.1, BCL2 and 70 
C/EBPβ (9, 10).  71 
 72 
Epstein-Barr virus (EBV) is a human herpesvirus that immortalizesB lymphocytes and is 73 
associated with the development of numerous lymphomas including Burkitt’s lymphoma 74 
(BL), HL and DLBCL. MiR-155 expression is upregulated on B cell infection by EBV 75 
(11). In in vitro EBV transformed B cell lines (lymphoblastoid cell lines; LCLs) and an 76 
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EBV-positive DLBCL cell line, loss of miR-155 expression inhibits cell growth and 77 
induces apoptosis, indicating that miR-155 expression is important for transformed B cell 78 
survival (12). MiR-155 expression in LCLs appears to attenuate high levels of NF-B 79 
signaling and this may help promote B cell proliferation and prevent apoptosis (13). 80 
Consistent with a key role for gene regulation by miR-155 in viral-induced oncogenesis, 81 
the oncogenic herpesviruses Kaposi’s sarcoma herpesvirus and Marek’s disease herpes 82 
virus encode miR-155 mimics in their viral genomes (14-16).   83 
 84 
Two EBV genes essential for B cell transformation upregulate miR-155 expression; the 85 
constitutively-active CD40 receptor mimic, latent membrane protein 1 (LMP1) and the 86 
viral transcription factor, Epstein-Barr virus nuclear antigen 2 (EBNA2) (12, 13). 87 
Expression of either LMP1 or EBNA2 independently activates transcription of miR-88 
155HG (13). Upregulation of AP-1 and NF-B activity by LMP1 appears to play an 89 
important role in activation of the miR-155 promoter in EBV-infected cells (17, 18). The 90 
mechanism of EBNA2 activation of miR-155 has not been demonstrated. EBNA2 is 91 
required for B cell immortalization by EBV and activates all viral gene promoters, 92 
including LMP1, so indirect activation of miR-155 via upregulation of LMP1 is a likely 93 
consequence of EBNA2 expression (19, 20). However, EBNA2 also deregulates host 94 
gene transcription by binding to promoter and enhancer elements (21, 22). Enhancer and 95 
super-enhancer activation by EBNA2 appears to be widespread in the B cell genome (22-96 
24). For example, EBNA2 activation of the MYC proto-oncogene is directed by the 97 
targeting of upstream enhancers and modulation of enhancer-promoter looping (21, 25). 98 
EBNA2 does not bind DNA directly and associates with viral and cellular gene 99 
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regulatory elements through its interactions with cellular transcription factors that include 100 
RBPJ, PU.1 and EBF1 (26).  101 
 102 
An EBNA2-bound super-enhancer postulated to control miR-155 expression was 103 
identified in LCLs based on the binding of a number of EBV transcription factors 104 
(EBNA2, EBNA3A, EBNA3C and EBNA-LP), binding of NF-B subunits and broad 105 
and high histone H3 lysine 27 acetylation (H3K27ac) signals (24). However, the original 106 
region identified actually comprises the highly-expressed 20 kb miR-155HG transcription 107 
unit from which miR-155 is derived. A subsequent study using RNA pol II chromatin 108 
interaction analysis by paired-end tag sequencing (ChIA-PET) found that RNA pol II 109 
associated with a number of EBNA2-bound promoter, enhancer and super-enhancer 110 
regions upstream of miR-155HG that formed links with the miR-155HG promoter (27). 111 
Whether EBNA2 can activate miR-155HG transcription via the miR-155HG promoter or 112 
these putative enhancer elements however has not been investigated.  113 
 114 
MiR-155 expression is also activated by interferon regulatory factor 4 (IRF4) through an 115 
interferon-stimulated response element (ISRE) in the miR-155HG promoter (28). 116 
Interestingly, IRF4 levels are highly upregulated in EBV infected cells and like miR-155, 117 
IRF4 is also induced by both LMP1 and EBNA2 (29). As a result, IRF4 and miR-155 118 
levels correlate in EBV-infected cells. In addition to the potential indirect effects of 119 
EBNA2 on IRF4 expression via LMP1 upregulation, conditional expression of EBNA2 in 120 
the presence of protein synthesis inhibitors also demonstrates that IRF4 is a direct target 121 
gene of EBNA2 (30). The mechanism of EBNA2 activation of IRF4 has not been 122 
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demonstrated. IRF4 expression is essential for the growth and survival of LCLs and 123 
apoptosis induced by IRF4 depletion can be partially rescued by expression of miR-155 124 
(28, 31). This indicates that the upregulation of miR-155 by IRF4 may be a key 125 
component of its essential role in promoting LCL growth. 126 
 127 
To obtain information on how the IRF4/miR-155 expression network is controlled by 128 
EBV, we investigated the role of putative upstream EBNA2-bound enhancer elements in 129 
the regulation of miR-155HG and IRF4 expression. At both gene loci we identified 130 
specific EBNA2-bound enhancer elements that activate transcription of their respective 131 
promoters in an RBPJ-dependent manner. Deletion of the EBNA2-responsive miR-132 
155HG enhancer resulted in a decrease in miR-155HG transcription in EBV-infected 133 
cells demonstrating its importance for the maintenance of miR-155 expression.  These 134 
data identify key enhancer elements utilized by EBV for the control of two genes critical 135 
for B cell growth that is relevant to the study of miR-155 and IRF4 deregulation in other 136 
tumor contexts. 137 
 138 
RESULTS 139 
A miR-155HG upstream enhancer is activated by EBNA2 through RBPJ 140 
To obtain information on regulatory elements that may control miR-155 expression, we 141 
examined miR-155HG promoter interaction data obtained from the EBV-infected 142 
GM12878 LCL and CD34+ hematopoietic progenitor cells using  the genome-wide 143 
chromosome conformation technique, capture Hi-C (CHi-C) (32). In CHi-C, promoter 144 
interactions are captured from Hi-C genomic interaction libraries using RNA baits that 145 
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uniquely hybridize to approximately 22,000 human promoters. These data demonstrate 146 
that in both GM12878 and CD34+ cells the miR-155HG promoter interacts with three 147 
main upstream regions marked by high levels of H3K27ac, indicating transcription 148 
regulatory function (Figure 1A and B). These include two intergenic regions and an 149 
intragenic region proximal to the promoter of the LINC00158 non-coding RNA gene . 150 
The same miR-155HG interacting regions were also detected by RNA pol II ChIA-PET 151 
(27). Interestingly, CHi-C data demonstrates that the miR-155 genomic locus within exon 152 
3 of miR-155HG interacts at a much lower frequency with the two intergenic regions 153 
(Figure 1C). This suggests that these interactions more frequently involve the miR-154 
155HG promoter, consistent with a role in regulating transcription. The miR-155 155 
genomic locus does however interact with the LINC00158 promoter-proximal region, 156 
consistent with a gene to gene looping interaction between miR-155HG and LINC00158 157 
(Figure 1C). The miR-155HG-LINC00158 interaction is also the main interaction 158 
detected in this region by ChiA-PET for the chromatin organizing factor CTCF, 159 
suggesting it may be involved in domain organization rather than miR-155HG promoter 160 
regulation (27). Our EBNA2 chromatin immunoprecipitation sequencing (ChIP-seq) data 161 
from the same GM12878 LCL used for CHi-C detects the highest EBNA2 binding at two 162 
sites within the most proximal intergenic interacting region (23) (Figure 1A). We 163 
therefore investigated the role of these two EBNA2-bound putative enhancers (E1 and 164 
E2) in the regulation of miR155-HG. 165 
 166 
We generated luciferase reporter plasmids containing the miR-155HG promoter and one 167 
or both enhancer elements. Reporter assays carried out in the EBV negative B cell line 168 
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DG75 in the absence or presence of transient EBNA2 expression demonstrated that 169 
EBNA2 had no effect on the miR-155HG promoter but activated transcription up to 170 
approx. 7-fold when a region encompassing both E1 and E2 was inserted upstream of the 171 
promoter (Figure 2A). The level of activation was similar to that observed for the 172 
EBNA2 responsive EBV C promoter (Figure 2B). When testing each enhancer 173 
separately, we found that the presence of E1 alone did not convey EBNA2 174 
responsiveness, but it increased basal transcription levels compared to the promoter alone 175 
by approximately 2-fold (Figure 2A). This indicates that E1 has EBNA2-independent 176 
enhancer function. EBNA2 activated transcription via E2 alone up to approx. 11-fold 177 
indicating that E2 is an EBNA2-responsive enhancer (Figure 2A). Interestingly, the 178 
presence of E2 decreased basal transcription levels approximately 5-fold compared to the 179 
promoter alone (Figure 2A). This is consistent with the presence of repressive elements in 180 
the enhancer that can limit basal transcription activity, a feature we observed previously 181 
for some of the EBNA2-responsive enhancer elements at RUNX3 and RUNX1 (23). As a 182 
result, the overall level of transcription in the presence of E2 was lower than that in the 183 
presence of E1 and E2 combined (Figure 2A). Since EBNA2 upregulates IRF4 and IRF4 184 
is a known activator of miR-155HG, we investigated whether the effects of EBNA2 in 185 
these reporter assays may be indirect and the result of increased endogenous IRF4 186 
expression. We found that transient expression of EBNA2 did not increase endogenous 187 
IRF4 expression (Figure 2A and B). This indicates that longer-term expression or a pre-188 
formed chromatin signature at the regulatory elements involved is important for 189 
activation of endogenous IRF4 by EBNA2. We conclude that EBNA2-independent and 190 
EBNA2-dependent enhancers regulate miR-155HG transcription in EBV-infected cells 191 
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and that EBNA2 activates transcription directly via association with a specific miR-192 
155HG enhancer. 193 
 194 
EBNA2 binds to many target gene enhancers through the cell transcription factor RBPJ 195 
(CBF1)(21). We investigated whether EBNA2 activation of miR-155HG E2 was 196 
mediated via RBPJ. ChIP-QPCR analysis of RBPJ binding in the GM12878 LCL 197 
detected RBPJ binding at E2 and not E1, consistent with a role for RBPJ in EBNA2 198 
activation of E2 (Figure 2C). To confirm this, we carried out reporter assays in a DG75 199 
RBPJ knock-out cell line (33). This cell line was derived from a different parental DG75 200 
cell line that also lacks IRF4 expression, so for comparison we also carried out reporter 201 
assays in the parental DG75 wild type cell line (Figure 2D). Our data demonstrated that 202 
EBNA2 activated transcription of the miR-155HG E1 and E2 containing reporter 203 
construct in the wild type DG75 cell line to the same extent as the EBV C promoter 204 
control, confirming our previous results (Figure 2D). However in DG75 RBPJ knock-out 205 
cells, the activation of this reporter construct by EBNA2 was almost completely 206 
abolished (Figure 2D). This mirrored the loss of EBNA2 activation observed for the 207 
RBPJ-dependent viral C promoter (Figure 2E). These data also provide further evidence 208 
that EBNA2 activation of miR-155HG E2 is not an indirect effect mediated by IRF4 209 
upregulation and we confirmed that IRF4 expression is not induced by EBNA2 in this 210 
cell background (Figure 2D).  211 
 212 
Interestingly, EBNA2 binding sites often coincide with binding sites for IRF4 or IRF4-213 
containing transcription complexes, indicating that IRF4 may be involved in EBNA2 214 
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binding to DNA (24, 34). However, our results indicate that IRF4 is not required for 215 
EBNA2 targeting of miR-155HG E2 enhancer element since EBNA2 activation was 216 
efficient in the absence of IRF4 (Figure 2D). We conclude that EBNA2 can directly 217 
upregulate miR-155HG transcription through a distal RBPJ-dependent enhancer (E2) 218 
independently of IRF4. 219 
 220 
IRF4 independently activates miR-155HG via promoter and enhancer elements 221 
Our data demonstrate that IRF4 is not required for the effects of EBNA2 on miR-155HG 222 
transcription. However, IRF4 can independently activate the miR-155HG promoter 223 
through an ISRE (28). It is not known whether IRF4 can also activate miR-155HG 224 
transcription through enhancer elements. We therefore tested whether exogenous 225 
expression of IRF4 in DG75 cells can activate miR-155HG transcription via upstream 226 
enhancers. Because IRF4 activates the control plasmid (pRL-TK), firefly reporter activity 227 
was normalized to actin expression as a previously described alternative in these assays 228 
(35). Consistent with published data, we found that exogenous expression of IRF4 229 
resulted in a 4-fold increase in miR-155HG promoter activity (28). The presence of E1 230 
did not result in any further increase in miR-155HG transcription by IRF4 (Figure 3). 231 
However, the additional presence of E2 increased the activation of the miR-155HG 232 
reporter to approx. 10-fold. These data demonstrate that miR-155HG E2 is IRF4-233 
responsive and contributes to IRF4 activation of miR-155HG transcription.  234 
 235 
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Taken together our results indicate that miR-155HG promoter activation by IRF4 and the 236 
independent effects of IRF4 and EBNA2 on a specific miR-155HG enhancer contribute to 237 
the high-level expression of miR-155HG and miR-155 in EBV-infected B cells. 238 
 239 
An IRF4 upstream enhancer is activated by EBNA2 through RBPJ 240 
Our data support a role for IRF4 as a key regulator of miR-155HG expression in EBV-241 
infected cells. IRF4 is also an EBNA2 target gene, but the mechanism of IRF4 242 
upregulation by EBNA2 has not been defined (28, 30). RNA pol II ChiA-PET analysis 243 
recently identified a number of upstream regions that interact with IRF4 in the GM12878 244 
LCL (27). These include the transcription unit of DUSP22, an intergenic region upstream 245 
from DUSP22 predicted to be a super-enhancer and intergenic regions between IRF4 and 246 
DUSP22. The upstream super-enhancer linked to both DUSP22 and IRF4, so likely 247 
represents an important regulatory region (27). EBNA2 ChIP-sequencing data that we 248 
obtained using EBV-infected cells derived from a BL cell line additionally identified two 249 
large EBNA2 binding peaks within the region 35 kb directly upstream of IRF4 (Figure 250 
4A). We investigated the potential role of these regions in EBNA2 activation of IRF4. 251 
These putative proximal and distal EBNA2-bound enhancer regions are referred to as 252 
IRF4 enhancer 1 (E1) and IRF4 enhancer 2 (E2), respectively (Figure 4A). Luciferase 253 
reporter assays carried out in the two different DG75 cell line clones in the absence or 254 
presence of transient EBNA2 expression demonstrated that EBNA2 had little effect on 255 
the IRF4 promoter (Figure 4B and D). The presence of IRF4 E1 reduced basal 256 
transcription by 2-fold and increased EBNA2 activation up to approx. 7-fold similar to 257 
the level of EBNA2 activation observed for the EBV C promoter (Figure 4B). The 258 
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additional inclusion of IRF4 E2 alongside IRF4 E1 had little further effect on EBNA2 259 
activation (Figure 4B). These data indicate that IRF4 E1 acts as an EBNA2-responsive 260 
enhancer. Consistent with EBNA2 activation through RBPJ, ChIP-QPCR detected RBPJ 261 
binding at IRF4 E1 and not E2 (Figure 4C). Accordingly, EBNA2 activation of the IRF4 262 
enhancer construct was decreased from aprrox. 6-fold to approx. 2-fold in RBPJ knock 263 
out cells. Our data therefore demonstrate that EBNA2 can activate IRF4 transcription 264 
through an RBPJ-dependent enhancer (E1) located 13 kb upstream from the transcription 265 
start site (TSS). 266 
 267 
Deletion of miR-155HG E2 from the B cell genome reduces mIR-155HG expression 268 
Since EBNA2 and IRF4 can activate transcription through miR-155HG E2 in reporter 269 
assays, we next tested the role of this enhancer in the regulation of mIR-155HG in EBV-270 
infected B cells. To do this, we used CRISPR/Cas9 gene editing to remove the region 271 
encompassing E2 (Figure 5A) from the genome of the EBV-immortalized LCL IB4. We 272 
designed two single guide RNAs (sgRNAs), one targeting a region 5’ to the enhancer and 273 
one targeting a region 3’ to the enhancer, so that DNA repair following Cas9 cleavage 274 
would generate an E2 deletion (Figure 5A). Both sgRNAs comprised 20 nucleotide 275 
sequences that target the genomic region adjacent to a protospacer adjacent motif (PAM) 276 
required for Cas9 cleavage (Figure 5C). sgRNAs were transfected into IB4 cells 277 
alongside Cas9 protein and single cell clones were generated by limiting dilution. PCR 278 
screening was used to identify cell line clones containing E2 deletions using a forward 279 
primer located 5’ of the E2 region and a reverse primer located 3’ of E2 to amplify a 180 280 
bp DNA product across the deletion site (Figure 5A and B). This primer set did not 281 
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amplify DNA from intact templates containing E2 as the amplicon was too large (1.75 282 
kb) for efficient amplification under the conditions used. For three cell line clones tested 283 
(C4D, C2B and C5B) we detected amplification of a 180 bp PCR product consistent with 284 
the presence of an E2 deletion (Figure 5B). We did not detect this PCR product in 285 
parental IB4 cells and an additional clone, C4A indicating that this cell line clone did not 286 
contain a deletion (Figure 5B). Sequencing of the PCR products amplified across the 287 
deletion site confirmed the E2 deletion (Figure 5C). Clones C4D and C2B contained 288 
deletions consistent with cleavage by Cas9 three bases upstream from the PAM sequence 289 
as expected, and the subsequent ligation of the cleaved ends. Clone C5B had an 290 
additional deletion of 8 nucleotides at the 5’ cut site indicating loss of a small amount of 291 
additional DNA during the DNA repair and religation process (Figure 5C). 292 
 293 
We next used real-time PCR analysis to determine whether deletion of miR-155HG E2 294 
affected the levels of endogenous miR-155HG RNA in IB4 cells. We found that all three 295 
deletion mutant cell line clones had reduced levels of miR-155HG transcripts compared 296 
to parental IB4 cells or the non-deleted C4A cell line (Figure 5D). miR-155HG RNA 297 
expression was reduced by 47%, 63% and 78% in cell line clones C4D, C2B and C5B, 298 
respectively (Figure 5D). This indicates that the RBPJ-dependent EBNA2-responsive 299 
enhancer (E2) located 60 kb upstream of miR-155HG plays an important role in 300 
maintaining miR-155HG expression in EBV-infected cells. Given that miR-155 is 301 
derived by processing of the miR-155HG transcript, our data indicate that this enhancer 302 
would be important in controlling miR-155 expression.  303 
 304 
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In summary we have identified and characterized new enhancer elements that play a key 305 
role in the direct and indirect upregulation of miR-155 expression in EBV-infected cells 306 
by the EBV transcription factor EBNA2 (Figure 6). Importantly, we show that an 307 
EBNA2 and IRF4 responsive enhancer element located 60 kb upstream from the miR-308 
155HG TSS is essential to maintain high-level miR-155HG RNA expression. 309 
 310 
DISCUSSION 311 
Enhancer control of miR-155HG by EBV 312 
We have characterized an enhancer 60 kb upstream of the miR-155-encoding gene miR-313 
155HG that is bound by EBNA2, the key transcriptional regulator encoded by EBV. This 314 
enhancer (enhancer 2) was responsive to EBNA2 in reporter assays and EBNA2 315 
activation was dependent on the expression of host cell protein RBPJ. Since EBNA2 316 
cannot bind DNA directly, this is in line with EBNA2 binding via its interaction with 317 
RBPJ (36, 37). We found that the presence of miR-155HG enhancer 2 in the B cell 318 
genome was important to maintain the miR-155HG expression level in an EBV-infected 319 
B cell line. Given that this enhancer is EBNA2 responsive in reporter assays, it is likely 320 
that EBNA2 activation of enhancer 2 plays a key role in maintaining miR-155HG 321 
expression in EBV-infected cells. Since enhancer 2 contains binding sites for a number of 322 
other B cell transcription factors (e.g. SPI1 (PU.1), RUNX3, NF-B rel A, BATF and 323 
SRF), it is possible that these factors also contribute to the maintenance of miR-155HG 324 
expression in EBV-infected cells.   MiR-155 depletion has been shown to impair the 325 
growth of EBV-infected cells (12), but although we found that deletion of enhancer 2 326 
reduced miR-155HG expression, we observed variable growth rates across our control 327 
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and miR-155 deletion clones (data not shown). It is therefore likely that previous studies 328 
using a miRNA sponge to deplete miR-155 achieved much larger reductions in miR-155 329 
levels than we observed. In our cells miR-155 expression is still detectable as a result of 330 
promoter activation by IRF4 and the likely influence of other more distal enhancers (see 331 
below), so differences in growth may not be detectable. 332 
 333 
MiR-155HG enhancer 2 is located within a region upstream of miR-155HG that is 334 
detected by CHi-C and RNA pol II ChIA-PET to associate with the miR-155HG 335 
promoter. Although, another putative enhancer bound by EBNA2 in the GM12878 LCL 336 
(enhancer 1) is also present in this region, we found that enhancer 1 was not EBNA2 337 
responsive but did upregulate transcription from the miR-155HG promoter in reporter 338 
assays. This indicates that this region possesses EBNA2-independent enhancer function. 339 
The detected EBNA2 binding at enhancer 1 may therefore be the consequence of looping 340 
between enhancer 1 and enhancer 2 that would lead to the indirect precipitation of this 341 
region of DNA in EBNA2 ChIP-seq experiments. This has been described for other TFs 342 
e.g. (38).  Interestingly, binding at enhancer 1 is not detected by EBNA2 ChIP-seq in a 343 
BL cell background (22), so its activity and looping interactions may be cell-type 344 
dependent. Indirect immunoprecipitation of the miR-155HG promoter as a result of 345 
looping interactions with EBNA2-bound enhancers may also explain the presence of an 346 
EBNA2 peak at the miR-155HG promoter despite the fact that the promoter is not 347 
consistently or highly EBNA2 responsive in reporter assays. 348 
 349 
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Two further upstream regions also interact with the miR-155HG promoter by CHi-C and 350 
RNA pol II ChIA-PET in LCLs (one intergenic and one proximal to the LINC00158 351 
promoter) (Figure 6). This is consistent with the presence of an active enhancer-promoter 352 
hub formed between two intergenic enhancer regions (one of which encompasses 353 
enhancer 2) and the promoter-proximal regions of miR-155HG and LINC00158. In two 354 
EBV-infected LCL backgrounds (GM12878 and IB4), maximal EBNA2 (and RBPJ) 355 
binding at the miR-155HG locus is detected in the intergenic interacting region 356 
encompassing miR-155HG enhancer 2 (21, 23, 27). This is despite the classification of 357 
the remaining intergenic region and the LINC00158 promoter proximal region as EBV 358 
super-enhancers based on their chromatin and TF landscape profiles (27). It is therefore 359 
possible that EBNA2 accesses the miR-155HG enhancer hub and upregulates miR-155 360 
expression through its RBPJ-dependent association with miR-155HG enhancer 2. Our 361 
observations highlight the importance of testing the EBNA2 responsiveness of EBNA2-362 
bound regions rather than relying on binding profiles alone to assign EBNA2 enhancer 363 
function. 364 
 365 
The constitutively active EBV membrane protein LMP1 also activates miR-155HG 366 
transcription. NF-B and AP-1 sites in the miR-155HG promoter have been shown to be 367 
important to maintain miR-155HG promoter activity in LCLs and two NF-B sites and 368 
the AP-1 site mediate LMP1 responsiveness in transiently-transfected EBV negative cells 369 
(17, 18). NF-B RelA also binds to the miR-155HG enhancer 2 region and the putative 370 
upstream super-enhancer, so it is also possible that LMP1 activation of the NF-B and 371 
AP-1 pathways also activates miR-155HG enhancers. Thus promoter (and possibly 372 
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enhancer) activation by LMP1 and enhancer activation by EBNA2 may all contribute to 373 
the high-level miR-155 expression observed in EBV-infected cells.  374 
 375 
miR-155HG activation by IRF4 376 
Our results also revealed that the B cell transcription factor IRF4 can activate miR-377 
155HG transcription via enhancer 2 in addition to its known effects on the miR-155HG 378 
promoter. IRF4 activates the miR-155HG promoter via an ISRE. There are no ISREs 379 
within miR-155HG enhancer 2, but the sequence encompassing the PU.1 binding site 380 
partially matches an ETS-IRF composite element (EICE), so IRF4 could bind this 381 
element in combination with the ETS protein PU.1. This putative EICE is located approx. 382 
500 bp away from the only match to the RBP-J consensus motif in enhancer 2 so we do 383 
not anticipate any competition between IRF4 and EBNA2/RBP-J in activation of the 384 
miR-155HG enhancer. 385 
 386 
Enhancer control of IRF4 by EBV 387 
EBNA2 also indirectly influences miR-155HG expression through the transcriptional 388 
upregulation of IRF4 and we demonstrated that this is mediated through an upstream 389 
enhancer. In addition to the presence of an EBNA2-bound super-enhancer upstream of 390 
the neighboring DUSP22 gene (27), we found that EBNA2 can also upregulate IRF4 391 
transcription through an RBPJ-dependent enhancer located in an intergenic region 13 kb 392 
upstream from IRF4. This is consistent with recent reports of IRF4 as an RBPJ-dependent 393 
EBNA2 target gene (39). At IRF4 and DUSP22, EBNA2 therefore likely targets multiple 394 
enhancers and super-enhancers.  395 
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 396 
miR-155 as a therapeutic target 397 
MiR-155 is overexpressed in many tumor contexts, including hematological malignancies 398 
and is implicated in cancer therapy resistance (10). It therefore represents an important 399 
therapeutic target. Preliminary results from a phase I clinical trial using an anti-miR to 400 
miR-155 in patients with cutaneous T cell lymphoma showed that the anti-miR is well 401 
tolerated when injected intratumorally (40). Inhibition of miR-155 expression through 402 
indirect transcriptional repression has also been tested in acute myeloid leukemia cells 403 
using an inhibitor of the NEDD8-activating enzyme (41). NEDD8-dependent ubiquitin 404 
ligases regulate NF-B activity and their inhibition by MLN4924 in AML cells results in 405 
reduced binding of NF-B to the miR-155HG promoter and a reduction in miR-155 406 
expression. In mice engrafted with leukemic cells, MLN4924 treatment reduced miR-155 407 
expression and increased survival. These data provide evidence for transcriptional 408 
inhibition of miR-155 as a therapeutically viable strategy.  409 
 410 
The sensitivity of super-enhancers to transcriptional inhibitors is also being exploited as a 411 
therapeutic strategy in various tumor contexts. Super-enhancers often drive the high-level 412 
expression of oncogenes, and super-enhancer inhibition by CDK7 and BET inhibitors can 413 
effectively block tumor cell proliferation and enhance survival in mouse models of 414 
disease (42-44). MiR-155 expression in human umbilical vein endothelial cells is 415 
sensitive to inhibition by BET and NF-B inhibitors (45). This was proposed to result 416 
from inhibition of an upstream miR-155 super-enhancer, but the region examined 417 
actually represents the miR-155HG transcription unit, which has high-level 418 
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H3K27ac(used as a super-enhancer marker) throughout its length when miR-155HG is 419 
transcriptionally active. Nonetheless, the study highlights the usefulness of transcription 420 
inhibitors in reducing miR-155 expression. Our identification and characterisation of the 421 
enhancers that drive miR-155HG transcription in B cells may therefore underpin 422 
therapeutic opportunities for the inhibition of miR-155 expression in numerous B cell 423 
cancer contexts where miR-155 is a key driver of tumor cell growth. 424 
   425 
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METHODS 426 
Cell lines 427 
All cell lines were cultured in RPMI 1640 media (Invitrogen) supplemented with 10% 428 
Fetal Bovine serum (Gibco), 1 U/ml penicillin G, 1 µg/ml streptomycin sulphate and 292 429 
µg/ml L-glutamine at 37
o
C in 5% CO2. Cells were routinely passaged twice-weekly. The 430 
DG75 cell line originates from an EBV negative BL (46). DG75 cells cultured in our 431 
laboratory (originally provided by Prof M. Rowe) express low levels of IRF4, but DG75 432 
cells obtained from Prof B. Kempkes (referred to here as DG75 wt parental cells) lack 433 
IRF4 expression. The DG75 RBPJ (CBF1) knock-out cell-line (SM224.9) was derived 434 
from DG75 wt parental cells (33). IB4 (47) and GM12878 (obtained from Coriell Cell 435 
Repositories) are EBV-immortalized lymphoblastoid cell lines (LCLs) generated by 436 
infection of resting B cells in vitro. 437 
  438 
 Plasmid construction 439 
The miR-155HG promoter sequence from -616 to +515 (Human GRCh37/hg19 chr 21 440 
26933842-26934972) was synthesized by GeneArt Strings® (Invitrogen) to include XhoI 441 
and HindIII restriction enzyme sites and cloned into pGL3 basic (Promega) to generate 442 
the pGL3miR-155HG promoter construct. The pGL3miR-155HG enhancer 1 (E1) 443 
construct was generated in a similar way by synthesis of the promoter and upstream E1 444 
region (chr21 26884583-26885197) as a single DNA fragment that was then cloned into 445 
pGL3 basic. To generate the miR-155HG promoter E1 + E2 construct, the promoter and 446 
E1 and E2 regions (chr21 26873921-26875152) were synthesized as a single DNA 447 
fragment and cloned into pGL3 basic. The pGL3miR-155HG promoter E2 construct was 448 
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generated using sequence and ligation independent cloning. The E2 region was amplified 449 
by PCR from the miR-155HG promoter E1 + E2 construct using primers containing 450 
vector and insert sequences (forward 5’ 451 
TCTTACGCGTGCTAGCCCGGGCTCGAGGAGAGGTTTAAAGCACTCAGACAGC 452 
3’ and reverse 5’ 453 
GGGCTTTGAGAACGTTTGTACCTCGAGGATCTAGAACCTCTGGAGTTGGAGA454 
T 3’). The pGL3miR-155HG promoter vector was digested with XhoI and then T4 DNA 455 
polymerase was used to further resect the cut ends to allow the insert to anneal to 456 
extended single-stranded regions of the vector. Single-strand DNA gap filling occurred 457 
through DNA repair following transformation of the plasmid into E.coli. 458 
 459 
The IRF4 promoter sequence from -739 to +359 (Human GRCh37/hg19 chr6 391024-460 
392121) was synthesized by GeneArt (Invitrogen) and the promoter fragment was 461 
amplified from the supplied vector (pMK-RQ) using primers to introduce XhoI 462 
restriction sites at each end (forward 5’ GTCTCGAGATTACAGGCTTGAGCCACA 3’, 463 
reverse 5’GACTCGAGCTGGACTCGGAGCTGAGG 3’). The promoter was then 464 
cloned into the XhoI site of pGL3 basic (Promega) to generate the pGL3IRF4 promoter 465 
construct. IRF4 enhancer 1 (E1) (chr6 377854-379089) was amplified from genomic 466 
DNA using primers to introduce NheI and XhoI sites (5’ forward 467 
GAGCTAGCATCGCTTGAGGTTGCAGTG 3’ and reverse 5’ 468 
GTCTCGAGTGAAGCAGGCACTGTGATTC 3’ ). The XhoI site was end filled using 469 
Klenow and the E1 fragment was cloned upstream of the promoter into the NheI and 470 
SmaI sites of the pGL3 IRF4 promoter construct. E2 (chr6 365659-366654) was 471 
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amplified by PCR using primers designed to introduce SacI and NheI sites (forward 5’ 472 
GAGAGCTCAGCCATCTCCATCATCTGGT 3’ reverse  5’ 473 
GAGCTAGCATGTGGAACGCTGGTCC 5’) and cloned upstream of E1 into the SacI 474 
and NheI sites of the pGL3IRF4 promoter E1 construct. 475 
 476 
Luciferase reporter assays  477 
DG75 cell lines were electroporated with plasmid DNA at 260 V and 950 µF (BioRad 478 
Gene Pulser II) using 0.4cm cuvettes and luciferase assays carried out as described 479 
previously with some modifications (48). Briefly, DG75 cells were diluted 1:2 into fresh 480 
medium 24 hours prior to electroporation. For transfection, cells were pelleted and 481 
conditioned media reserved for later use. Cells were then resuspended in serum-free 482 
media to a density of 2x10
7
 cells/ml. 500 µl of cell suspension was pre-mixed with DNA 483 
and then added to the cuvette and immediately electroporated. Transfected cells were 484 
then transferred to 10 ml of pre-warmed conditioned media, and cultured for 48 hours in 485 
a humidified incubator at 37°C, with 5% CO2. 486 
Cells were transfected with 2µg of the pGL3 luciferase reporter plasmids and 0.5µg pRL-487 
TK (Promega) as a transfection control where indicated. Transfection reactions also 488 
included 10 or 20 µg of the EBNA2 expressing plasmid (pSG5 EBNA2), 5 or 10 µg of 489 
IRF4 expressing plasmid (pCMV6XL5-IRF4, Cambridge Biosciences) or empty vector 490 
control. One tenth of each transfection was processed for Western blotting to analyse 491 
EBNA2, IRF4 and actin protein expression levels. The remaining cells were lysed and 492 
firefly and Renilla luciferase activity measured using the dual luciferase assay (Promega) 493 
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and a Glowmax multi detection system (Promega). For transfections where IRF4 was 494 
expressed, firefly luciferase signals were normalized to actin expression. 495 
 496 
CRISPR 497 
CRISPR guides were designed using www.benchling.com to excise miR-155HG 498 
enhancer 2 from the B cell genome in the IB4 LCL by targeting genomic regions located 499 
5’ and 3’ of the enhancer. Guides were selected that had an on-target and off-target score 500 
that was above 60% (26873822 CTATCCTTAACAGAACACCC and 26875376 501 
TTTAACTAGAACCTTAGACA) and then ordered as TrueGuide Modified Synthetic 502 
sgRNAs from GeneArt (Invitrogen). IB4 cells were diluted 1:2 into fresh medium 24 503 
hours prior to transfection. 1x10
6
 cells were then washed in PBS, pelleted and 504 
resuspended in 25 µl of resuspension Buffer R (Invitrogen). The guide RNA and Cas9 505 
mix was prepared by adding 7.5 pmol of GeneArt TrueCut Cas9 Protein V2 (Invitrogen) 506 
and 7.5 pmol of sgRNAs to 5 μl of resuspension Buffer R and incubating at room 507 
temperature for 10 minutes. 5 μl of cell suspension (2 x105 cells) was then mixed with 7ul 508 
of the Cas9/sgRNA complex. 10ul of the cell Cas9/sgRNA mix was then electroporated 509 
using the Neon transfection system (Invitrogen) at 1700V for 20 ms with 1 pulse. 510 
Transfections were carried out in duplicate and electroporated cells were immediately 511 
transferred to two separate wells of a 24 well plate containing 0.5 ml of pre-warmed 512 
growth media. Cells were kept in a humidified incubator at 37°C, with 5% CO2 for 72 513 
hours. Cells were then sequentially diluted over a period of 2 weeks and subject to 514 
limited dilution in 96-well plates to obtain single cell clones. Cell line clones were 515 
screened by PCR for genomic deletion using the PHIRE Tissue Direct PCR Master Mix 516 
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kit (Thermo Scientific). The forward primer (5’ AAATTCCGTGGCTAGCTCCA 3’) 517 
hybridized to a region 5’ of enhancer 2 and a reverse primer targeted a region 3’ to 518 
enhancer 2 (5’ CTGCTAAGGGAATGTTGAACAAA 3’). Deletions were confirmed by 519 
DNA sequencing of the PCR product generated using the forward PCR primer. 520 
 521 
SDS-PAGE and Western Blotting 522 
SDS-PAGE and Western blotting was carried out as described previously (48, 49) using 523 
the anti-EBNA2 monoclonal antibody PE2 (gift from Prof M. Rowe) anti-actin 1/5000 524 
(A-2066, Sigma) and anti-IRF4 1/2000 (sc6059, Santa Cruz). Western blot visualization 525 
and signal quantification was carried out using a Li-COR Imager. 526 
  527 
ChIP-QPCR 528 
ChIP-QPCR for RBPJ was carried out as described previously (23). MiR-155HG  locus 529 
primers were located in the miR-155HG  promoter (forward 5’ 530 
AGCTGTAGGTTCCAAGAACAGG 3’ and  reverse 5’ 531 
GACTCATAACCGACCAGGCG 3’, miR-155HG enhancer 1 (forward 5’ 532 
ACCTGTTGACTTGCCTAGAGAC 3’ and reverse 5’ TTCTGGTCTGTCTTCGCCAT 533 
3’), a ‘trough’ region between miR-155HG enhancer 1 and enhancer 2 (forward 5’ 534 
TATTCAGCTATTCCAGGAGGCAG 535 
3’ and reverse 5’ GTGACATTATCTGCACAGCGAG 3’), and miR-155HG enhancer 2 536 
(forward 5’ CCTAGTCTCTCTTCTCCATGAGC 3’ and reverse 5’ 537 
AGTTGATTCCTGTGGACCATGA 3’). IRF4 locus primers were located in the IRF4 538 
promoter (forward 5’ TCCGTTACACGCTCTGCAA 3’ and reverse 5’ 539 
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CCTCAGGAGGCCAGTCAATC 3’), a ‘trough’ region between the IRF4 promoter and 540 
enhancer 1 (forward 5’ TGTGACAAGTGACGGTATGCT 3’ and reverse 5’ 541 
TTGTAACAGCGCCTAATGTTGG 3’), IRF4 enhancer 1 (forward 5’ 542 
TTACCACCTGGGTACCTGTCT 3’ and reverse 5’ ACAGTAGCATGCAGCACTCTC 543 
3’) and IRF4 enhancer 2 (forward 5’ AGTGAGACGTGTGTCAGAGG 3’ and reverse 5’ 544 
AAGCAGGCACTGTGATTCCA 3’). 545 
 546 
 RT-QPCR  547 
Total RNA was extracted using TriReagent (Sigma) and RNA samples then purified 548 
using the RNeasy kit (Qiagen). RNA concentrations were determined using a Nanodrop 549 
2000 (Thermo Scientific) and 1 μg was used to prepare cDNA using the ImProm II 550 
reverse transcription kit with random primers (Promega). Quantitative PCR was 551 
performed in duplicate using the standard curve absolute quantification method on an 552 
Applied Biosystems 7500 real-time PCR machine as described previously (22) using 553 
published QPCR primers for miR-155HG (BIC) (28) (forward 5’ 554 
ACCAGAGACCTTACCTGTCACCTT3’ and reverse 5’ 555 
GGCATAAAGAATTTAAACCACAGATTT 3’) and GAPDH (forward 5’ 556 
TCAAGATCATCAGCAATGCC 3’ and reverse 5’ CATGAGTCCTTCCACGATACC 557 
3’) 558 
 559 
Capture Hi-C 560 
Previously described capture Hi-C data from GM12878 and CD34+ cells were examined 561 
for interactions that were captured using baits comprising a 13,140 bp HindIII fragment 562 
encompassing the miR-155HG promoter (GRCh38/hg19 chr21:26926437-26939577) and 563 
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a 2,478 bp HindIII fragment that encompasses the miR-155 genomic sequence in exon 3 564 
(GRCh38/hg19 chr21:26945874-26948352). 565 
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FIGURE LEGENDS 755 
FIG 1. EBNA2 binding and chromosome interactions at the miR-155HG locus on 756 
chromosome 21. (A) EBNA 2 ChIP-sequencing in the EBV-infected LCL GM12878 (23) 757 
showing the number of sequencing reads from EBNA2-enriched DNA plotted per million 758 
input-subtracted total reads and aligned with the human genome. The position of called 759 
peaks (MACs p<10
-7
) is indicated (black lines). The positions of the two main EBNA2-760 
bound putative enhancer regions are indicated (E1 and E2). H3K27ac signals in 761 
GM12878 ChIP-seq available from ENCODE are also shown. (B) Capture Hi-C 762 
interaction data obtained using a HindIII fragment encompassing the miR-155HG 763 
promoter as bait. Interacting fragments were captured from Hi-C libraries generated from 764 
GM12878 or CD34+ progenitor cells (32). Data show the normalized accumulation of 765 
raw read counts of the interaction di-tags anchored on the bait regions. The geometric 766 
mean shows the average number of reads for each fragment and its immediate 767 
neighboring fragments colored according to a rainbow scale.. The main interacting 768 
regions are shown in boxes with dashed lines (C) Capture Hi-C interaction data obtained 769 
using a HindIII fragment encompassing the miR-155 genomic locus as bait. The main 770 
interacting region is shown in the box with dashed lines. 771 
 772 
FIG 2. The effects of EBNA2 on miR-155HG promoter and enhancer elements. (A) mIR-773 
155HG luciferase reporter assays in the presence or absence of EBNA2.  DG75 cells 774 
were transfected with 2 µg of pGL3 firefly luciferase reporter constructs containing the 775 
miR-155HG promoter either alone or in the presence of enhancer E1, E2 or both E1 and 776 
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E2. Assays were carried out in the absence or presence of 10 or 20 µg of the EBNA2-777 
expressing plasmid pSG5-EBNA2 and 0.5 µg of Renilla luciferase control plasmid (pRL-778 
TK). Firefly luciferase signals were normalized to Renilla luciferase signals and 779 
expressed relative to the signal obtained for the miR-155HG promoter in the absence of 780 
EBNA2. Results show the mean of three independent experiments -/+ standard deviation. 781 
Fold activation by EBNA2 relative to the signal obtained for each construct in the 782 
absence of EBNA2 is shown above each bar. Western blot analysis of EBNA2 and IRF4 783 
expression is shown below each bar chart, with actin providing a loading control. All 784 
blots shown were probed at the same time with the same batch of antibody solution and 785 
for each protein show the same exposure. They are therefore directly comparable, but 786 
have been cut and placed to align with the respective luciferase assay graphs. The asterisk 787 
shows the position of a non-specific band visible on longer exposures of EBNA2 blots. 788 
(B) EBNA2 activation of an EBV C promoter reporter construct was used as a positive 789 
control. (C) ChIP-QPCR analysis of RBPJ binding at the miR-155HG locus in GM12878 790 
cells. Precipitated DNA was analysed using primer sets located at the promoter, E1, E2 791 
and in a trough between E1 and E2 (T). EBNA2 binding at the transcription start site of 792 
PPIA and at the previously characterised CTBP2 binding site were used as negative and 793 
positive binding controls, respectively. Mean percentage input signals, after subtraction 794 
of no antibody controls, are shown plus or minus standard deviation for three independent 795 
ChIP experiments. (D) Luciferase reporter assays carried out using the miR-155HG 796 
promoter or miR-155HG E1 and E2 construct in DG75 wt parental cells that lack IRF4 797 
expression and the corresponding RBPJ knock out cell line.  Results are displayed as in 798 
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(B). (E). Luciferase reporter assays carried out as in (D) using the RBP-Jdependent C 799 
promoter reporter construct. 800 
 801 
FIG 3. The effects of IRF4 on miR-155HG promoter and enhancer elements. DG75 cells 802 
were transfected with 2 µg of pGL3 firefly luciferase reporter constructs containing the 803 
miR-155HG promoter either alone or in the presence of enhancer E1, E2 or both E1 and 804 
E2. Assays were carried out in the absence or presence of 5 or 10 µg of the IRF4-805 
expressing plasmid pCMV6XL5-IRF4. Western blot analysis of IRF4 and actin 806 
expression is shown below the bar chart. Blots shown were probed at the same time with 807 
the same batch of antibody solution and for each protein show the same exposure. They 808 
are therefore directly comparable, but have been cut and placed to align with the 809 
respective luciferase assay graphs. One set of samples was split over two gels. Firefly 810 
luciferase signals were normalized to actin western blot signals and fold activation 811 
relative to the signal for each construct in the absence of EBNA2 is shown. Results show 812 
the mean of three independent experiments -/+ standard deviation.  813 
 814 
FIG 4. The effects of EBNA2 on IRF4 promoter and enhancer elements. (A) EBNA2 815 
ChIP-sequencing reads at the IRF4 locus in Mutu III BL cells. The number of sequencing 816 
reads from EBNA2-enriched DNA are plotted per million input-subtracted total reads and 817 
aligned with the human genome. The position of called peaks (MACS p<10
-7
) are 818 
indicated (black boxes) (22). The positions of the two main EBNA2-bound putative 819 
enhancer regions are indicated (E1 and E2). (B) IRF4 luciferase reporter assays in the 820 
presence or absence of EBNA2.  DG75 cells were transfected with 2 µg of pGL3 firefly 821 
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luciferase reporter constructs containing the IRF4 promoter either alone or in the 822 
presence of enhancer E1 or both E1 and E2. Assays were carried out in the absence or 823 
presence of 10 or 20 µg of the EBNA2-expressing plasmid pSG5-EBNA2 and 0.5 µg of 824 
Renilla luciferase control plasmid (pRL-TK). Firefly luciferase signals were normalized 825 
to Renilla luciferase signals and expressed relative to the signal obtained for the IRF4 826 
promoter in the absence of EBNA2. EBNA2 activation of an EBV C promoter reporter 827 
construct was used as a positive control. Results show the mean of three independent 828 
experiments -/+ standard deviation. Fold activation by EBNA2 relative to the signal 829 
obtained for each construct in the absence of EBNA2 is shown above each bar. Western 830 
blot analysis of EBNA2 is shown below each bar chart, with actin providing a loading 831 
control. All blots shown were probed at the same time with the same batch of antibody 832 
solution and for each protein show the same exposure. They are therefore directly 833 
comparable, but have been cut and placed to align with the respective luciferase assay 834 
graphs.  (C) ChIP-QPCR analysis of RBPJ binding at the IRF4 locus in GM12878 cells. 835 
Precipitated DNA was analysed using primer sets located at the promoter, E1, E2 and in a 836 
trough between the promoter and E1 (T). EBNA2 binding at the transcription start site of 837 
PPIA and at the previously characterised CTBP2 binding site were used as negative and 838 
positive binding controls, respectively. Mean percentage input signals, after subtraction 839 
of no antibody controls, are shown plus or minus standard deviation for three independent 840 
ChIP experiments. (D) Luciferase reporter assays carried out using the IRF4 promoter, 841 
IRF4 E1 and E2 construct and the RBPJdependent C promoter reporter construct in 842 
DG75 wt parental cells and the corresponding RBPJ knock out cell line.  Results are 843 
displayed as in (B). 844 
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 845 
FIG 5. The effects of CRIPSR/Cas9-mediated deletion of miR-155HG enhancer 2. (A) 846 
EBNA2 ChIP-sequencing reads in GM12878 cells (23) and H3K27ac ChIP-seq signals in 847 
GM12878 from ENCODE at the miR-155HG enhancer 2 region as in Figure 1. The 848 
locations of the guide RNAs used for CRISPR gene editing and the PCR primers used for 849 
screening cell clones are indicated. (B) PCR analysis of single cell clones obtained by 850 
limited deletion following transfection of guide RNAs and Cas 9 protein using primers 851 
that span the deletion site and only efficiently amplify a product (180 bp) from templates 852 
carrying an E2 deletion. (C) DNA sequence of the deletion spanning PCR products from 853 
the C4A, C2B and C5B cell lines. Black uppercase text shows the sequence present in the 854 
PCR products and blue lowercase text shows the 5’ and 3’ ends of the deleted region, 855 
with forward slashes showing the position of the remaining ~1.5 kb of deleted DNA. The 856 
sgRNA target sequences are underlined and PAM sequences are shown in grey. (D) 857 
QPCR analysis of total RNA extracted from IB4 parental cells or cell line clones using 858 
primers specific for miR-155HG and GAPDH. miR-155HG signals were normalized by 859 
dividing by GAPDH signals and expression levels are shown relative to the signal in IB4 860 
parental cells. Results show the mean -/+ standard deviation of PCR duplicates from a 861 
representative experiment.  862 
 863 
FIG 6. Model for enhancer activation of IRF4 and miR155HG by EBV EBNA2. EBNA2 864 
targets an intergenic enhancer 13 kb upstream of IRF4 via RBPJ. A super-enhancer 865 
upstream of DUSP22 bound by EBNA 2 also links to both DUSP22 and IRF4. IRF4 then 866 
activates miR-155HG via the promoter and an intergenic enhancer located 60 kb 867 
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upstream. EBNA2 activates the miR-155HG upstream enhancer via RBPJ. The miR-868 
155HG promoter also links to an additional upstream region and the LINC00158 gene. 869 
Curved red lines indicate chromosomal interactions. 870 
 871 
 872 
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